[{"id":"d494a72a-9ff2-45f5-b7e1-6d9a0c5e5875","acronym":"","url":"https://clinicaltrials.gov/study/NCT05503797","created_at":"2022-08-17T14:55:09.900Z","updated_at":"2025-02-25T14:09:04.053Z","phase":"Phase 2","brief_title":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","source_id_and_acronym":"NCT05503797","lead_sponsor":"Fore Biotherapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plixorafenib (FORE-8394) • Tybost (cobicistat)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 02/21/2023","start_date":" 02/21/2023","primary_txt":" Primary completion: 06/27/2025","primary_completion_date":" 06/27/2025","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2025-02-17"},{"id":"72272cbc-c9f7-4112-ac79-128d9c683b5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06610682","created_at":"2025-02-26T07:01:00.356Z","updated_at":"2025-02-26T07:01:00.356Z","phase":"Phase 1","brief_title":"Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib","source_id_and_acronym":"NCT06610682","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plixorafenib (FORE-8394) • Tybost (cobicistat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/10/2025","start_date":" 01/10/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2025-01-13"},{"id":"66017a7e-e1f3-43a3-a59a-3c773b2ee231","acronym":"AUGMENT-101","url":"https://clinicaltrials.gov/study/NCT04065399","created_at":"2021-01-18T19:55:07.775Z","updated_at":"2024-07-02T16:35:03.156Z","phase":"Phase 1/2","brief_title":"A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation","source_id_and_acronym":"NCT04065399 - AUGMENT-101","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" KMT2A • NUP98","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • NUP98 rearrangement","tags":["KMT2A • NUP98"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • NUP98 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Revuforj (revumenib) • Tybost (cobicistat)"],"overall_status":"Recruiting","enrollment":" Enrollment 413","initiation":"Initiation: 11/05/2019","start_date":" 11/05/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-17"},{"id":"9fe9336c-203b-4e85-b83d-ab26cb858495","acronym":"OSIBOOST-2","url":"https://clinicaltrials.gov/study/NCT05748093","created_at":"2023-02-28T13:01:31.374Z","updated_at":"2024-07-02T16:35:06.690Z","phase":"Phase 4","brief_title":"Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat","source_id_and_acronym":"NCT05748093 - OSIBOOST-2","lead_sponsor":"Maastricht University Medical Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Tybost (cobicistat)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-05-01"},{"id":"28864250-4433-4c9c-964c-52252987b833","acronym":"OSIBOOST","url":"https://clinicaltrials.gov/study/NCT03858491","created_at":"2021-01-18T19:02:15.962Z","updated_at":"2024-07-02T16:36:03.480Z","phase":"Phase 1","brief_title":"Pharmacokinetic Boosting of Osimertinib","source_id_and_acronym":"NCT03858491 - OSIBOOST","lead_sponsor":"Academisch Ziekenhuis Maastricht","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Tybost (cobicistat)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 11/01/2020","start_date":" 11/01/2020","primary_txt":" Primary completion: 10/31/2021","primary_completion_date":" 10/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-09-26"}]